Neurocrine Biosciences | NBIX - Дебиторская задолженность





Дебиторская задолженность Изменить Дата
AbbVie USD 12.48B 110M 2026-03
Acadia Pharmaceuticals USD 166.33M 17.95M 2026-06
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
ALKERMES USD 456.48M 48.85M 2026-06
Alnylam Pharmaceuticals USD 912.74M 28.78M 2026-06
Amgen USD 10.23B 1.09B 2026-06
Biogen USD 1.79B 76.6M 2026-03
BioMarin Pharmaceutical USD 1.06B 157.13M 2026-06
Cytokinetics USD 6.83M 10.94M 2026-03
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Exelixis USD 322.21M 6.73M 2026-06
Gilead Sciences USD 5.06B 314M 2026-06
Halozyme Therapeutics USD 453.33M 4.66M 2026-06
Incyte USD 1.13B 73.7M 2026-06
Ionis Pharmaceuticals USD 58.84M 15.16M 2026-06
Nektar Therapeutics USD 3.6M 1.82M 2026-03
Neurocrine Biosciences USD 887M 118.9M 2026-06
Pfizer USD 16.19B 19M 2026-06
Prothena USD 5.16M 0 2023-12
Regeneron Pharmaceuticals USD 6.57B 834.4M 2026-06
Repligen USD 157.71M 6.16M 2026-06
Rigel Pharmaceuticals USD 28.9M 1.39M 2024-06
Sarepta Therapeutics USD 393.8M 154.11M 2026-06
Teva Pharmaceutical Industries USD 3.49B 100M 2026-06
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Vertex Pharmaceuticals USD 2.13B 138.2M 2026-06